Table 1.
Demographic and baseline characteristics
| Characteristic | Value |
|---|---|
| Age at diagnosis - yr | |
| Median | 65 |
| Range | 48 – 77 |
| Sex - no. (%) | |
| Male | 12 (80) |
| Female | 3 (20) |
| Race or ethnic group - no. (%)a | |
| White | 11 (73) |
| Black | 3 (20) |
| Other | 1 (7) |
| ECOG - no. (%) | |
| 0 | 10 (66) |
| 1 | 5 (33) |
| Extrahepatic spread - no. (%) | |
| Present | 9 (60) |
| Absent | 6 (40) |
| Macroscopic vascular invasion - no (%) | |
| Present | 5 (33) |
| Absent | 10 (66) |
| Childs Pugh Score - no. (%) | |
| A | 15 (100) |
| B7 | 0 (0) |
| Barcelona Clinic liver cancer stage - no. (%) | |
| B | 3 (20) |
| C | 12 (80) |
| Prior systemic therapy - no. (%) | |
| 0 | 9 (60) |
| 1–2 | 4 (27) |
| >2 | 2 (13) |
| Prior liver directed therapy - no. (%) | |
| Yes | 13 (87) |
| No | 2 (13) |
| History of infectious hepatitis - no. (%) | |
| Hepatitis C | 7 (47) |
| Hepatitis B | 2 (13) |
| No history of infectious hepatitis | 6 (40) |
| Biochemical analysis | |
| Albumin - g/dL | |
| Median | 3.8 |
| Range | 2.9 – 4.4 |
| Total bilirubin - mg/dL | |
| Median | 0.6 |
| Range | 0.3 – 1.6 |
| Alpha-fetoprotein - ng/mL | |
| Median | 26.6 |
| Range | 3.6 – 13×104 |
a
Race was reported by the investigator